Share >  
Share
Share on Tumblr

Oglemilast

News »

   latest by relevance
Glenmark ends foray with Oglemilast drug
May 17, 2010 at 08:47 | Source: CNBC-TV18
Glenmark's Phase II-B study for Oglemilast does not meet primary end point. CNBC-TV18s Ekta Batra reports on what it means for the company.
Growth prescription: Glenn Saldanha on Glenmark in 2010
Jan 19, 2010 at 19:37 | Source: CNBC-TV18
The recent ruling by the Federal Trade Commission may impact the generics industry. So says Glenn Saldanha, MD and CEO of Glenmark. In an interview with CNBC-TV18, Saldanha spoke about the recent FTC ruling, revenue kickers and out-licensing deals in 2010.
Glenmark expects interest costs to come down in Q3
Oct 30, 2009 at 14:02 | Source: Moneycontrol.com
Glenmark Pharmaceuticals declared its second quarter results for the financial year 2010. The companys Q2 consolidated net profit was down at Rs 80.9 crore versus Rs 117.3 crore and its consolidated net sales were up at Rs 590.3 crore versus Rs 559.7 crore
Expect FY10 topline to grow by 20-25%: Glenmark
Oct 29, 2009 at 15:43 | Source: CNBC-TV18
In an interview with CNBC-TV18, Glenn Saldanha, Managing Director and Chief Executive Officer, Glenmark Pharmaceuticals spoke about the companys results.
Glenmark may find support at Rs 200-205: Udayan Mukherjee
Aug 21, 2009 at 09:26 | Source: CNBC-TV18
Glenmark Pharma lost 20% in last few days as Forest Labs said Oglemilast did not show positive results in phase II-B Glenmark outlicenced Oglemilast to Forest Labs. Managing Editor of CNBC-TV18, Udayan Mukherjee said Oglemilast disappointment has been priced in very quickly by the market.
Glenmark's fair value at Rs 160, says BNP Paribas
Aug 19, 2009 at 10:59 | Source: CNBC-TV18
Anmol Ganjoo, Vice President, BNP Paribas Securities said he always maintained low chances of Oglemilasts success and added that he not betting on asthma indication of the drug. BNP Paribas, Ganjoo said, had ascribed zero value to Oglemilast and it has a target price of Rs 160 per share for Glenmark.

Videos »
Glenmark ends foray with Oglemilast drug
Growth prescription: Glenn Saldanha on Glenmark in 2010
Expect FY10 topline to grow by 20-25%: Glenmark
Glenmark may find support at Rs 200-205: Udayan Mukherjee
Glenmark's fair value at Rs 160, says BNP Paribas
more »

Photos »

  /  

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window